Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Med Clin (Barc) ; 162(9): e33-e39, 2024 05 17.
Article in English, Spanish | MEDLINE | ID: mdl-38458959

ABSTRACT

BACKGROUND: The wound-healing process in diabetic foot is affected by pro and anti-inflammatory markers, and any disruption in the inflammatory reaction interferes with tissue homeostasis, leading to chronic non-wound healing. AIM: This study aimed to determine the diagnostic value and effect of CRP, IL-6, TNF, and HbA1c on initiation the and progression of diabetic foot ulcers. METHOD: ELISA was used to quantify IL-6, TNF, CRP, and HbA1c in 205 patients with diabetes, and 105 were diabetic foot free. The prevalence and progression of diabetic foot were also evaluated. The area under the curve (AUC) was calculated using the receiver operating characteristic (ROC) curve to analyze the predictive values. Forward stepwise logistic regression analysis was used to compute the odds ratio (OR) and the corresponding 95% confidence intervals (CIs). RESULTS: CRP, IL-6, and FBS were found to be significant predictors of diabetic foot (OR=1.717, 95% CI=1.250-2.358, P=0.001; OR=1.434, 95% CI=1.142-1.802, P=0.002; and OR=1.040, 95% CI=1.002-1.080, P=0.037), respectively. The AUCs for CRP, IL-6, and HbA1c in predicting diabetic foot were 0.839, 0.728, and 0.834, respectively, demonstrating a good predictive value for each diagnostic marker. CONCLUSION: The current study demonstrated that IL-6, CRP, and HbA1c may be useful biomarkers to indicate diabetic foot progression. Furthermore, our findings showed a substantial relationship between CRP and HbA1c in individuals with diabetic foot conditions.


Subject(s)
Biomarkers , C-Reactive Protein , Diabetes Mellitus, Type 2 , Diabetic Foot , Disease Progression , Glycated Hemoglobin , Interleukin-6 , Tumor Necrosis Factor-alpha , Humans , Diabetic Foot/blood , Diabetic Foot/diagnosis , Diabetic Foot/etiology , Female , Male , Biomarkers/blood , Middle Aged , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Case-Control Studies , Glycated Hemoglobin/analysis , Interleukin-6/blood , C-Reactive Protein/analysis , Aged , Tumor Necrosis Factor-alpha/blood , ROC Curve , Logistic Models , Predictive Value of Tests
2.
Proc Natl Acad Sci U S A ; 117(11): 6042-6046, 2020 03 17.
Article in English | MEDLINE | ID: mdl-32111690

ABSTRACT

Induction of longstanding immunologic tolerance is essential for survival of transplanted organs and tissues. Despite recent advances in immunosuppression protocols, allograft damage inflicted by antibody specific for donor organs continues to represent a major obstacle to graft survival. Here we report that activation of regulatory CD8 T cells (CD8 Treg) that recognize the Qa-1 class Ib major histocompatibility complex (MHC), a mouse homolog of human leukocyte antigen-E (HLA-E), inhibits antibody-mediated immune rejection of heart allografts. We analyzed this response using a mouse model that harbors a point mutation in the class Ib MHC molecule Qa-1, which disrupts Qa-1 binding to the T cell receptor (TCR)-CD8 complex and impairs the CD8 Treg response. Despite administration of cytotoxic T lymphocyte antigen 4 (CTLA-4) immunoglobulin (Ig), Qa-1 mutant mice developed robust donor-specific antibody responses and accelerated heart graft rejection. We show that these allo-antibody responses reflect diminished Qa-1-restricted CD8 Treg-mediated suppression of host follicular helper T cell-dependent antibody production. These findings underscore the critical contribution of this Qa-1/HLA-E-dependent regulatory pathway to maintenance of transplanted organs and suggest therapeutic approaches to ameliorate allograft rejection.


Subject(s)
Graft Rejection/immunology , Heart Transplantation/adverse effects , Histocompatibility Antigens Class I/immunology , T-Lymphocytes, Helper-Inducer/metabolism , T-Lymphocytes, Regulatory/immunology , Allografts/immunology , Allografts/metabolism , Animals , Disease Models, Animal , Graft Rejection/blood , Graft Rejection/genetics , Graft Survival/immunology , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/metabolism , Humans , Immune Tolerance , Isoantibodies/immunology , Isoantibodies/metabolism , Isoantigens/immunology , Isoantigens/metabolism , Mice , Myocardium/immunology , Myocardium/metabolism , Point Mutation , Receptors, Antigen, T-Cell/immunology , Receptors, Antigen, T-Cell/metabolism , T-Lymphocytes, Helper-Inducer/immunology , Transplantation, Homologous/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...